Kodiak Sciences (KOD) upcoming phase III wet AMD data could provide upside following the stock's recent pullback, amid expectations that tarcocimab and KSI-501 will achieve non-inferiority, UBS said in a note.

UBS expects tarcocimab to meet non-inferiority to Eylea 2mg in the DAYBREAK trial, with dosing intervals potentially reaching 3 to 3.5 months. The company is expected to report topline data by the end of September, with a presentation at the American Academy of Ophthalmology (AAO) on Oct. 9, UBS said.

UBS also expects KSI-501 to meet non-inferiority, while any numerically superior trends would provide additional upside. The bank also expects December data as another potential catalyst.

UBS maintained a buy rating with an $80 price target.

Price: 30.78, Change: -0.74, Percent Change: -2.35